Cytokine-activated receptors initiate intracellular signaling by recruiting protein kinases that phosphorylate the receptors on tyrosine residues, thus enabling docking of SH2 domainbearing activating factors. Here we report that in response to type 1 interferon (IFNa), IFNa receptors recruit cytoplasmic CREB-binding protein (CBP). By binding to IFNaR2 within the region where two adjacent proline boxes bear phospho-Ser364 and phospho-Ser384, CBP acetylates IFNaR2 on Lys399, which in turn serves as the docking site for interferon regulatory factor 9 (IRF9). IRF9 interacts with the acetyl-Lys399 motif by means of its IRF homology2 (IH2) domain, leading to formation of the ISGF3 complex that includes IRF9, STAT1, and STAT2. All three components are acetylated by CBP. Remarkably, acetylation within the DNA-binding domain (DBD) of both IRF9 and STAT2 is critical for the ISGF3 complex activation and its associated antiviral gene regulation. These results have significant implications concerning the central role of acetylation in cytokine receptor signal transduction.
INTRODUCTION
IFNaR1 and IFNaR2 belong to class II transmembrane cytokine receptors that are shared by all type I IFN family members. Despite their similarity, neither one can function independently during signaling for IFNa. By binding to IFNaR1 and IFNaR2, IFNa triggers their oligomerization and receptor-associated Janus tyrosine kinase (JAK) activation, leading to receptor tyrosine phosphorylation. Among the cytoplasmic molecules responding to IFNa for activation, signal transducer and activator of transcription (STAT) proteins are the most prominent SH2 domain bearing transcription factors recruited by IFNa receptors for transcriptional regulation. Although IFNa can activate all seven STAT members, STAT1 and STAT2 activation have been most closely linked to IFNa's antiviral activity. While STAT2 can be recruited by both IFNaR2 and IFNaR1, STAT1 activation by IFNa mainly depends on the presence of STAT2 in the cell (Leung et al., 1995) . STAT2 binds to IFNaR2 much stronger than it binds to IFNaR1 , suggesting a prominent role of IFNaR2 in STAT recruitment and activation. However, STAT2 recruitment by IFNaR2 can be both IFNaR2 tyrosine phosphorylation-dependent and -independent Wagner et al., 2002) . Moreover, when STAT2 contains a bB Arg / Gln mutation in the SH2 domain, it can still be recruited by the IFNa receptor; and STAT1 and STAT2 still can form heterodimers independent of their phosphorylation status (Stancato et al., 1996; Li et al., 1997) . This indicates that additional posttranslational modification events may be involved in the IFNa receptor-STAT pathway activation.
STAT2 is notably distinct from the rest of STAT family members as its b-barrel DNA-binding domain (DBD) is essentially not involved in DNA binding. STAT2 acts as an adaptor to recruit STAT1 either to IFNaR2 for activation or to IRF9 to form the interferon-stimulated gene factor 3 (ISGF3) complex. The IFNa activated ISGF3 complex translocates to the nucleus, where it binds to the interferon-stimulated response element (ISRE) present in the promoters of many antiviral genes. Within the ISGF3 complex, IRF9 and STAT1 cooperatively contact the ISRE element at neighboring bases. The N-terminal domain (1-120 residues) of IRF9, a highly conserved helix-turnhelix structure among all IRF family members, is responsible for DNA binding. The C-terminal domain of IRF9, is also largely conserved among many IRF family members (except IRF1 and IRF2) and is homologous to the MAD homology2 (MH2) domain of SMAD proteins (Qin et al., 2003; Takahasi et al., 2003) . The MH2 domain of SMAD may play an important role in TGFb receptor association and SMAD dimerization (Wu et al., 2001) . It is worthwhile to note that the MH2 domain of SMAD3 is acetylated, suggesting a role of this domain in acetylation-relevant signal transduction (Inoue et al., 2006) . For IRF members, serine phosphorylation within the C-terminal regulatory domain is related to their activation by viruses or by Toll-like receptor ligation. In addition to C-terminal serine phosphorylation, both SMAD and IRF members undergo CBP/p300-mediated acetylation modification within their N-terminal DBD (Masumi et al., 2003; Caillaud et al., 2002) . Although CBP/p300 and cofactors exclusively enhance transcriptional activity of IRF or SMAD, the functional significance of acetylation within the DBD for transcriptional activity remains unclear.
The molecular mechanism of IRF9 activation leads to ISGF3 complex formation, and its subsequent DNA binding remains a critical missing link in understanding IFNa signaling. Recently, we showed that STAT3 activation by cytokines including IFNa required CBP/p300-mediated acetylation (Yuan et al., 2005) . The cytoplasm is a de facto arena for STAT to undergo dynamic posttranslational modifications, including both phosphorylation and acetylation, suggesting CBP/p300 may function as a cytoplasmic acetyltransferase in cells. In view of the direct interaction between CBP/p300 and STAT2, which is IFNa stimulation dependent and required for subsequent ISGF3 antiviral activity (Bhattacharya et al., 1996) , it is possible that CBP/p300 acetyltransferase activity is under the immediate regulation of the IFNa receptor. In this report, we demonstrate that in IFNa-treated cells IFNaR2 recruits CBP to initiate an acetylation cascade in cytoplasm. Although CBP exists mainly in nuclei of quiescent cells, IFNa treatment accelerates its cytoplasmic accumulation. A detailed protein-interaction analysis reveals that CBP-acetylated IFNaR2 and IRF9 undergo modular interaction, leading to ISGF3 activation. Thus, acetylation plays a critical role in activation of cytokine receptors and their downstream signaling molecules.
RESULTS

IFNaR2 Phosphorylation on Ser364 and Ser384
Coordinately Recruits Cytoplasmic CBP To investigate IFNa-stimulated acetylation of the ISGF3 components, we examined the subcellular localization of various HAT proteins before and after IFNa treatment of HeLa cells. Both p300 and CBP were detectable in the cytoplasmic fraction prepared from HeLa cells, albeit at relatively low levels. Upon IFNa treatment, however, the steady-state cytoplasmic CBP level was increased, accompanied by a gradual reduction of nuclear CBP levels ( Figure 1A ). This finding suggested that CBP may normally shuttle between the cytoplasm and the nucleus and that IFNa treatment can promote this process. Meanwhile, we observed that IRF9 and STAT2 nuclear translocation upon IFNa treatment ( Figure 1A ) is in agreement with the previous observation (Levy et al., 1989) . IFNa-mediated CBP nuclear export in HeLa cells as well as other type of cells was further documented by confocal laser microscopy analysis ( Figures 1B and S1A ). These findings prompted us to explore whether IFNa receptors could recruit CBP. In HeLa cells or mouse fibroblasts, CBP was associated with IFNaR2, and this association was enhanced upon IFNa treatment ( Figures 1C and S1B) . Similarly, IRF9 and IFNaR2 also coprecipitated ( Figure 1C ). It is worthwhile to note that the CBP and IFNaR2 coprecipitation was only detected in the cytoplasmic fraction, suggesting that IFNaR2 recruits CBP from the cytoplasm rather than from the nucleus ( Figure S1B ). The interaction between CBP and IFNaR2 detected in HeLa cells was confirmed by recovering IFNaR2 from anti-CBP precipitates prepared from 293T cells transiently transfected with HA-tagged IFNaR2 and HA-tagged CBP ( Figure 1D ). When IFNaR1 was cotransfected with CBP, IFNaR1 and CBP association was also detected (data not shown). In addition, both IFNaR2 and IFNaR1 were able to recruit p300 ( Figures S1C and S1D) . Thus, the two subunits of the IFNa receptor not only recruit JAK and STAT, as has been previously reported, but they also recruit CBP/ p300 and IRF9.
The cytoplasmic region of human IFNaR2 is serine rich and bears six putative proline boxes. To establish the CBP-binding domain, a series of cDNAs encoding a Myc-tagged IFNaR2 cytoplasmic region with various truncation were constructed ( Figure 1E ). In 293T cells, the Myc-IFNaR2 C-terminal truncation mutants were cotransfected with HA-CBP for an association analysis. Slightly enhanced CBP binding was detected when comparing the C-terminally truncated deletion construct (265-473) with the full-length C-terminal region (265-515) ( Figure 1F ), indicating that the C terminus of IFNaR2 bears an inhibitory regulation domain. IFNaR2 mutants interacted with CBP when the C-terminal end was truncated up to Ser392. Further truncation up to Gly335 largely disrupted the IFNaR2:CBP interaction ( Figure 1F ). In accord with this, while deletion of the membrane proximal region between Lys265 and Gly335 showed no apparent effect on IFNaR2:CBP interaction, further deletion up to Leu391 abrogated the IFNaR2:CBP interaction ( Figure 1F ).
Among the phosphoserines identified by mass spectrometry (Table S1 ), Ser364 and Ser384 reside within the two adjacent proline box 2 and proline box 3 (P362xxxxxPxxP, P378xxPxxxP) of the region between Gly335 and Ser391. To determine the importance of serine phosphorylation on CBP interaction, we prepared serine mutated IFNaR2. While IFNaR2 mutants with S322A/ S324A, S400A, or S412A/S413A substitutions retained their ability in recruiting CBP, either S364A or S384A of IFNaR2, but not with S364D or S384D substitution, largely abolished CBP recruitment ( Figure 1G ). Together, these results suggest that while the region from Gly335 to Ser392 is responsible for CBP binding, phosphorylation of Ser364 and Ser384 sites coordinately stabilize this binding.
IFNaR2 Acetylation by CBP on Lys399 Provides the Docking Site for IRF9 To gain insight into the role of cytoplasmic CBP recruitment by IFNa receptors, we examined IFNaR2 acetylation. In HeLa cells, IFNaR2 acetylation was induced by IFNa treatment and downregulation of CBP in HeLa cells with CBP-specific siRNA-abolished IFNaR2 acetylation in response to IFNa treatment (Figure 2A ), suggesting that CBP is responsible for IFNaR2 acetylation in HeLa cells. Although p300 and IFNaR2 interaction was detected ( Figure S1C ), CBP was much more effective than p300 or other acetyltransferase factors at catalyzing IFNaR2 acetylation ( Figure 2B , upper panel). CBP-dependent IFNaR2 acetylation could be enhanced by treating the transfectants with trichostatin A (TSA), a synthetic inhibitor of histone deacetylase (HDAC) or abolished by cotransfecting with HDAC6 ( Figure 2B , bottom panel), suggesting CBPmediated IFNaR2 acetylation is a reversible process.
The IFNaR2 cytoplasmic region carries a number of species-conserved lysine sites. To identify the acetylated lysine site(s), IFNaR2 mutants were constructed, in which each of these lysine residues was changed to arginine via site-directed mutagenesis. IFNaR2-KR mutants were transfected along with CBP in 293T cells and assessed for their acetylation pattern. IFNaR2 acetylation intensity was markedly reduced with the Lys399 / Arg substitution ( Figure 2C ), suggesting that Lys399 may be the major acetylation site of the IFNaR2 cytoplasmic region. To confirm this finding, IFNaR2 proteins purified from IFNatreated 293T transfectants were analyzed with MALDI-TOF mass spectrometry. The specific peptide sequences of IFNaR2 were assigned to the mass values shown in Figure 2D by matching the measured masses with calculated mass values. Mass spectrometry analysis not only confirmed Lys399 as the unique acetylation site but also identified seven phosphorylated serine residues including Ser400 ( Figure 2D and Table S1) as described in the above section. Notably, the peptides bearing acetyl-Lys399-phospho-Ser400 ( Figure 2D ), acetyl-Lys399 alone, and phospho-Ser400 alone (Table S1 ) were simultaneously recovered in the mass spectrometry analysis, indicating that Lys399 acetylation and Ser400 phosphorylation can happen either simultaneously or independently. Intriguingly, the ''RRKSPL'' motif of IFNaR2 is homologous to Lys9 and Lys27 of the histone H3 protein ( Figure 2E ). In histone H3, the ''RKS'' motifs are involved in protein interactions by following a ''meth/phos switch'' model (Fischle et al., 2005; Hirota et al., 2005) . This raises the possibility that the dual-mark combination of acetyl-Lys399phospho-Ser400 serves as a better protein-protein interaction module for signal transduction.
To explore the consequence of IFNaR2 acetylation in signal transduction, we analyzed STAT and IRF9 recruitment by IFNaR2, since IFNaR2 could recruit not only STAT2 but also IRF9 ( Figures 3A and 1C) . To identify the IRF9 docking site in IFNaR2, truncation mutations of IFNaR2 cytoplasmic domain were tested for IRF9 binding. C-terminally truncated IFNaR2 (265-408) interacted with IRF9 with no apparent binding defect ( Figure 3B , left panel). After further truncation up to Ser392 (265-392), the interaction with IRF9 was disrupted ( Figure 3B , left panel) without apparently affecting its interaction with STAT2 ( Figure 3B , right panel). Hence, the 16-residue fragment from Ser392 to Glu408 of the IFNaR2 cytoplasmic domain, which bears Lys399 and Ser400, should be specifically responsible for IRF9 binding.
To estimate Lys399/Ser400 modification in IRF9 recruitment, we constructed IFNaR2 with Lys399 and/or Ser400 mutations. IFNaR2-K399R reduced its interaction with IRF9 ( Figure 3C ). Interestingly, a slightly enhanced interaction between IFNaR2-S400A mutant and IRF9 was repeatedly observed ( Figure 3C ). When both K399R and S400A were introduced, however, the activity of IFNaR2 in IRF9 interaction was severely affected ( Figure 3C ). Mass spectrometry showed that IFNaR2 was phosphorylated on Ser322, Ser324, Ser412, and Ser413. A Ser / Ala substitution of these sites did not apparently affect the association of IFNaR2 and IRF9 ( Figure S2 ). To confirm the view that the acetyl-Lys399 or an acetyl-Lys399-phosphoSer400 motif is required for IRF9 binding, synthesized peptides containing the flanking sequence of Lys399/ Ser400 were immobilized at three doses on nitrocellulose membranes. Proteins prepared from control or Myc-IRF9 transfected 293T cells were incubated with these peptide membranes then followed by anti-Myc probing. Only the peptides bearing acetyl-Lys399 and acetyl-Lys399-phospho-Ser400 interacted with IRF9 ( Figure 3D ). Consistently, IFNa failed to induce the interaction between IFNaR2 and IRF9 ( Figure 3E ) or IRF9 nuclear translocation (data not shown) in CBPÀ/À mouse embryonic fibroblast (MEF). IFNa stimulation dependent IRF9 acetylation, nuclear translocation, and DNA-binding activity were restored by expressing wild-type IFNaR2 but not by expressing IFNaR2-K399R mutant in IFNaR2 null U5A cells ( Figure 3F) . These findings clearly demonstrate that CBP is responsible for IFNaR2 acetylation. Moreover, while IFNaR2 acetylation of Lys399 is sufficient for IRF9 recruitment, phosphorylation of the neighboring serine site (Ser400) further stabilizes the interaction between these two proteins.
The IRF9 IH2 Domain Is Responsible for the Modular Interaction with Acetylated IFNaR2
We next analyzed the domain of IRF9 responsible for the interaction with IFNaR2. The IRF9 C-terminal region can be further divided into three domains according to secondary structural analysis (http://www.sbg.bio.ic.ac.uk/ $3dpssm/index2.html): (1) the IRF homology1 domain (IH1D) or transcriptional activation domain (340-393) consists of a ''ba'' (or ''baa'' in other IRF members) secondary structure; (2) the IRF homology2 (IH2) domain (258-339) consists of four b sheets sandwiched by two helices, ''abbbba,'' similar to the SH2 domain ( Figure 4A ); and (3) the IRF homology3 (IH3) domain (200-257) consists of four short b sheets ''bbbb.'' To identify which of these C-terminal domains is required for IFNaR2 binding, we prepared a series of Myc-tagged IRF9 domain deletion mutants ( Figure 4B ) and cotransfected them with IFNaR2 in 293T cells. Coimmunoprecipitation results indicate that the IH2 domain (258-393) bears the major interaction site for IFNaR2, even though a weak interaction between the N-terminal DBD (1-117) and IFNaR2 was observed ( Figure 4C) . Deletion of the C-terminal IH1 domain (339-393) disrupted IRF9 interaction with STAT2 ( Figure 4D ). Given that the b5 and b6 motifs of the IH2 domain appear as the swapped bB and bC motifs in the SH2 domain ( Figure 4A ), we tested the significance of Arg292 of the IH2 domain for IFNaR2 binding. IRF9 with Arg292 / Gln substitution dramatically inhibited the IRF9 interaction with IFNaR2 ( Figure 4E ). Although conserved aromatic residues of the bromodomain often interact with the acetylated lysine site through amide-p interaction, substitution of conserved aromatic residues with alanine (IRF9-W300A, IRF9-F323F328A) did not affect IFNaR2 binding ( Figure 4E ). Together, these findings support the notion that the IH2 domain of IRF9 is responsible for the modular interaction with IFNaR2, whereas the IH1 domain of IRF9 is for STAT2 recruitment.
IRF9 Acetylation on Helix-a3 Lysine Is Required for IRF9 Dimerization and DNA Binding Like IFNaR2, IRF9 acetylation was inducible upon IFNa treatment in HeLa cells but not in the HeLa cells with CBP downregulated (Figure 5A ). CBP was also the most effective one among the acetyltransferases tested for catalyzing IRF9 acetylation in 293T cells ( Figure 5B ). For some IRF family members, the acetylated lysine sites have been exclusively identified within the N-terminal DBD ( Figure S2B ). To identify the acetylated lysine sites of IRF9, we mutated all conserved lysine sites within the IRF9 N-terminal domain. Surprisingly, in IRF9 null U2A cells, K / R mutagenic analysis of the IRF9 acetylation pattern did not provide any information regarding which lysine is acetylated by CBP because none of the IRF9-KR mutants appeared impaired by acetylation as accessed by blotting analysis ( Figure 5C ). Several IRF9-KR mutants became more sensitive to acetylation by CBP ( Figure 5C ), suggesting that IRF9 can be hypo-or hyperacetylated. When mass spectrometry was employed, eight acetylated peptides were recovered from IRF9 ( Figure 5D ). All acetylated lysine sites that reside within the N-terminal domain and are highly conserved in IRF9 through different species. When aligned with other IRF family members, however, Lys81, the helix-a3 lysine, is the only one conserved among all members (Figure S2B) .
In IRF2 and IRF7, the helix-a3 lysine (Lys78 and Lys92, respectively) is the major acetylation site and is thought to regulate DNA-binding activity (Caillaud et al., 2002; Masumi et al., 2003) . To determine an effect of IRF9 acetylation on DNA binding, we cotransfected either wild-type IRF9 or IRF9-KR mutants with CBP into U2A cells and performed EMSA using whole-cell extracts and a 32 Plabled ISRE oligonucleotide from the ISG15 gene promoter. IRF9-K81R virtually abolished its DNA-binding activity ( Figure 5E ). Three-dimensional and protein-interaction analysis revealed that the N-terminal DBD and the C-terminal transcriptional activation domain in a latent IRF molecule are either in contact or in close proximity and that dimerization is required for IRF to bind to DNA (Brass et al., 1996; Lin et al., 1999; Qin et al., 2003) . It was tempting to speculate that IRF9 acetylation on Lys81 was needed for IRF9 to undergo dimerization within two different domains. Coimmunoprecipitation results revealed that IRF-DBD but not IRF9-DBD with K81R substitution associated with IRF9 either full-length or the C-terminal 118-393 fragment ( Figure 5F , right panel). Thus, helix-a3 lysine acetylation plays a pivotal role in IRF dimerization, requiring an interaction between the N-terminal and C-terminal domains.
STAT2 Acetylation on Lys390
Regulates STAT2:STAT1 Interaction STAT2 is another important component of ISGF3 complex, and its acetylation was similar to IFNaR2 and IRF9 acetylation in many respects: CBP downregulation largely abolished STAT2 acetylation induction by IFNa (Figure 6A) , and CBP was more potent than transferases tested in catalyzing STAT2 acetylation ( Figure 6B ). Mass spectrometry identified nine acetylated lysine sites within STAT2 proteins prepared from 293T cells cotransfected with STAT2 and CBP or p300. While four acetyl-lysine sites reside within the b-barrel DBD ( Figure 6C ), others reside within the coiled coil and the SH2 domains (Table  S2) . Interestingly, and differing from IRF, acetylated lysine sites are poorly conserved among STAT members ( Figure 6D) .
To investigate the effect of STAT2 acetylation on ISGF3 complex formation, we started with the N-terminal coiledcoil domain. In agreement with previous publications (Horvath et al., 1996; Martinez-Moczygemba et al., 1997) , this domain of STAT2 (1-314) and IRF9 coprecipitated ( Figure S3A ). However, acetylation within the coiledcoil domain did not seem to be involved in this regulatory interaction since a K / R substitution of the four acetylated sites within this domain did not alter the STAT2: IRF9 interaction ( Figures S3B and S3C) .
We then examined STAT2 acetylation within the b-barrel DBD. A direct interaction between the STAT2-DBD (315-485) and STAT1 was detected ( Figure 6E ) (Li et al., 1997) . While STAT2 with a K384R or K419R substitution moderately weakened the STAT2 and STAT1 interactions, STAT2-K390R and to a lesser extent STAT2-K415R interacted more strongly with STAT1 ( Figure 6F , left panel). Among these acetylated sites within the b-barrel DBD, Lys390 is least conserved. Lys390 from STAT2 of human origin was replaced by glutamate in STAT2 of murine origin ( Figure S3D ). STAT2 with a K390E substitution restored the pattern of the interaction between STAT2 and STAT1 observed with wild-type STAT2 ( Figure 6G ). STAT1 also bears a negatively charged residue (Glu394) at the same position ( Figure 6D ). However, STAT1 with both E393 and E394 changed to alanine showed no effect on the elevated interaction between STAT1 and STAT2-K390R ( Figure 6G ). In contrast, STAT2 DBD acetylation seemed to be irrelevant to STAT2's interaction with IRF9 ( Figure 6F, right panel) or STAT3, which can also form heterodimer with STAT2 ( Figure S3E ). These findings imply that endogenous STAT1 and STAT2 in human cells might form a heterodimer prior to cytokine treatment. Indeed, we repeatedly detected a stable STAT1:STAT2 interaction, which was slightly diminished following IFNa treatment in HeLa cells ( Figure 6H ). To estimate STAT2-K390R mutant on ISGF3 complex formation, Myc-tagged forms of IRF9 and STAT1 were cotransfected with Myc-tagged STAT2 wild-type or K390R mutant in STAT2 null U6A cells. STAT1 precipitates prepared from these transfectants were blotted with either STAT2 antibody or IRF9 antibody, and their blotting signal intensities were plotted in arbitrary units ( Figure 6I ). Even though K390R mutated STAT2 became avidly bound to STAT1 ( Figure 6I, left) , lesser amount of IRF9 was recovered from STAT1 precipitants obtained from U6A cells expressing STAT2-K390R mutant ( Figure 6I , right). Although STAT1 was also acetylated (Kramer et al., 2006) , an effect of STAT1 acetylation (Figures S4A and S4B ) on the ISGF3 complex formation was not appreciated in this work. Recently, Mertens et al. suggested that activated STAT1 form homodimers via their SH2-domain interaction, whereas quiescent STAT1 form homodimers via their DBD interaction (Mertens et al., 2006) . Our results clearly indicate that STAT2:STAT1 interaction was mainly regulated by STAT2 acetylation on Lys390, which dissociates DBD of STAT2 from STAT1, a step required for the active ISGF3 complex formation. A CBP-Mediated Acetylation Cascade Plays a Critical Role in ISGF3 Antiviral Activity To investigate the significance of the CBP-mediated acetylation cascade on antiviral gene regulation by the ISGF3 complex, we manipulated CBP protein levels in cells. To do this, we first tested CBP overexpression on ISG54 promoter activation in 293T cells. Overexpression of CBP boosted the ISGF3 complex activity by a factor of 5-fold ( Figure 7A ). In contrast, introduction of the siRNA targeting CBP but not a control siRNA into the cells markedly inhibited ISGF3 transcriptional activity ( Figure S5A) . Importantly, the effect of STAT1 on IRF9 and STAT2 cotransfection-dependent transcriptional activity could be converted from weakly negative into largely positive by also cotransfecting CBP (comparing the last two groups in Figure 7A ). These findings support the notion that the conformational change of the STAT1:STAT2 heterodimer as regulated by STAT2 acetylation on the Lys390 site is critical for an active ISGF3 complex formation.
IFNaR2, IRF9, and STAT2 null cell lines developed by George Stark and coworkers were then used to examine acetylation of these factors on transcriptional activation. In U5A cells, the introduction of wild-type IFNaR2 restored the cellular response to IFNa in an ISG45 promoter-luciferase reporter assay ( Figure 7B, left) . With the same conditions, IRF9 docking site mutated IFNaR2, CBP binding site mutated IFNaR2, or wild-type IFNaR2 plus HDAC6 all abolished the cellular response to IFNa (Figure 7B, left) . When all KR mutants of IRF9 and STAT2 were tested, IRF9-K81R in U2A cells and STAT2-K390R in U6A cells failed to respond to IFNa in ISGF3 promoter reporter activation ( Figure 7B ; middle, right). We then prepared (B) IFNaR2, IRF9, and STAT2 of different mutation forms as indicated were tested for activation of ISG54 promoter-luciferase reporter in U5A, U6A, and U2A cells respectively. In U5A cells, HDAC6 and IFNaR2 cotransfection on ISG54 promoter-luciferase reporter activation was included. (C) U5A, U2A, and U6A cells transfected with indicated constructs were treated with or without IFNa for 1 hr. Genomic DNA elutes prepared from anti-ISGF3 precipitates were analyzed by ChIP assays with 6À16 promoter (6À16 Pm) primers. Genomic DNA without immunoprecipitation was used as input.
genomic DNA from these U5A, U2A, and U6A cells treated with IFNa for chromatin immunoprecipitation (ChIP) analysis. PCR products from ChIP experiments, corresponding to the region (À453 to À91) of the 6À16 gene promoter, which, centrally spanned with two ISRE motifs, were examined. The correct PCR products were enriched in response to IFNa treatment in the IRF9, and STAT2 were precipitates obtained only from those cells expressing wild-type IFNaR2, IRF9, or STAT2 but not from those cells transfected with empty vector or critical lysine mutants of IFNaR2, IRF9, or STAT2 ( Figure 7C ).
CBP-mediated acetylation of IFNa signaling factors were further analyzed in antiviral gene regulation. Since ISGF3 components failed to respond to IFNa for nuclear translocation in CBPÀ/À MEF ( Figure 7D ), the induction of antiviral genes 9À27, 6À16, ISG15, and ISG54 by IFNa was largely inhibited ( Figure 7E ). It further supports a critical role of CBP as a cytoplasmic acetyltransferase for IFNa signaling. In human lung fibrosarcoma 2fTGH cells, the parental line of U5A, U2A, and U6A cells, the above antiviral genes were all induced by IFNa in a time-dependent manner ( Figure S5B ). In U5A, introduction of wild-type but not K399R substituted IFNaR2 restored IFNa-dependent antiviral gene induction ( Figure 7F , left) and cell antiviral activity ( Figure 7G, left) . Cotransfection of HDAC6 with wild-type IFNaR2 abolished this IFNa-dependent cell antiviral activity in U5A cells ( Figure 7G, left) . Similarly, in U2A or U6A cells, introduction of wild-type but not specific K81R substituted IRF9 or K390R substituted STAT2 restored IFNa-dependent antiviral gene induction ( Figure 7F ; middle, right) and cell antiviral activity ( Figure 7G ; middle, right). Collectively, these results strongly support our conclusion that CBP-mediated IFNaR2 acetylation on Lys399, IRF9 acetylation on Lys81, and STAT2 acetylation on Lys390 function together in response to IFNa during antiviral signal transduction.
DISCUSSION
Tyrosine phosphorylation has long been considered to play the central role in signal transduction for many cytokines in mammalian cells. Here, we provide evidence that a CBP-mediated acetylation cascade together with serine phosphorylation plays a critical role in IFNa-initiated intracellular signaling ( Figure 7H ). Nuclear export of CBP upon UV stimulation has been previously noted (Cohen et al., 2004) . A serine phosphorylation-dependent mechanism may play a role in CBP nuclear exportation, similar to HDAC nuclear export (McKinsey et al., 2000) .
CBP/p300 can bind with many transcription factors at phosphoserine sites flanked with proline residues or negatively charged residues. In IFNaR2, phosphorylation of Ser364 and Ser384 sites may be further coordinated with the already negatively charged local environment for CBP recruitment. Given that Ser364, Ser384, and Ser400 sites are flanked with charged residues and proline, a kinesin spindle protein (KSP) type kinase may be responsible for their phosphorylation.
In histone H3, the ''RK9S'' or ''RK27S'' motif where lysine can be either methylated or acetylated serves as the docking site for heterochromatin protein 1 (HP1) or polycomb (Pc) (Fischle et al., 2003 (Fischle et al., , 2005 Hirota et al., 2005) . According to the ''methyl/phos switch'' model, serine phosphorylation of the ''RKS'' motif that engages an HP1 or Pc module could lead to consecutive loss of binding. In the IFNaR2 cytoplasmic region, acetylLys399 provides IRF9 with a docking site, whereas phosphorylation of the adjacent Ser400 seems to consolidate this interaction. In the SH2, WW, and MH2 domains, conserved arginine and aromatic residues often play critical roles in their modular interactions (Wu et al., 2001 ). In the IH2 domain, although those conserved aromatic residues may still provide an amide-p contact, b6-Arg (R292) seems to play a more important role in modulating interaction with the acetyl lysine presumably by providing a noncovalent contact.
Both IRF9 and STAT2 of an active ISGF3 complex are highly acetylated within their DBD. For transcription factors such as p53, acetylation within DBD mediates regulatory interaction with other cofactors without affecting its DNA-binding activity (Sykes et al., 2006; Tang et al., 2006) . For IRF family members, acetylation on the family conserved helix-a3 lysine within DBD presumably results in the conformational change (i.e., dimerization) required for DNA binding. In the case of IRF3, its dimerization requires serine phosphorylation within the ''serine rich loop-helix a5'' C tail to unlock the C-and N-terminal domains (Takahasi et al., 2003) . Lacking the C-terminal ''serine rich loop-helix a5'' tail, IRF9 dimerizes for DNA binding via Lys81 acetylation, a reminiscence of STAT3 acetylation on Lys685 for dimerization. In STAT2, Lys390 within DBD is poorly conserved. Although it is unclear whether Lys390 is an evolutionary mistake requiring acetylation for correction or it has a function evolved specially for human cells, STAT2 acetylation on this site may warrant a more flexible interaction between STAT2 and STAT1, allowing STAT1 to interact with IRF9 and DNA within the ISGF3 complex. CBP/p300 play a critical role in type I interferon antiviral activity. Adenovirus E1A inhibits IFNa response in the ISGF3 complex formation, STAT2 transactivity, and antiviral gene expression, allowing viral replication presumably by targeting CBP/p300 (Kalvakolanu et al., 1991; Bhattacharya et al., 1996) . In this respect, the profound impairment in IFNa-dependent viral-suppressive activities observed in CBP null cells is in agreement with the frequent loss of CBP/p300 activity in viral infected cells where the IFNa pathway is impaired. Although CBP is a transcriptional cofactor, which can affect ISGF3 transcriptional activity in nuclei, IFNaR2 failed to recruit IRF9, and both IRF9 and STAT2 failed to undergo nuclear translocation in response to IFNa treatment in CBPÀ/À MEF. Therefore, CBP can function as a primary cytoplasmic acetyltransferase for IFNa receptor signaling here. Our findings provide important molecular insights into the acetylation cascade in mediating cytokine receptor signal transduction.
EXPERIMENTAL PROCEDURES Cell Culture and Expression Constructs
All the cell lines were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum. STAT2, STAT1, IRF9, and IFNaR2 mutagenesis was performed using QuickChange XL site-directed mutagenesis kit (Stratagene, La Jolla, CA) or two-step PCR. IFNaR2 C-terminal tail truncation mutants, IRF9 domain deletion mutants, and STAT2 domain constructs were constructed by performing PCR amplification. PCR products were then subcloned into a pCDNA3.1 vector with a 6 3 Myc tag at the N terminus. All cDNA constructs used in this project were verified by sequencing. All transfections were performed with Lipofectamine 2000 (Invitrogen) in accordance with the manufacturer's instructions.
LC-MS/MS Mass Spectrometry Analysis of Proteins with Posttranslational Modifications
In 293T cells, IFNaR2, IFNaR1, IRF9, or STAT2 was cotransfected with CBP followed by IFNa treatment for 30 min or left no treatment. Immunoprecipitated IFNaR2, IFNaR1, IRF9, or STAT2 proteins from the transfectants were resolved by 10% SDS-PAGE and visualized using Coomassie blue stain. The bands of the above proteins (1-2 mg) were excised and subjected to mass spectrometry analysis performed by Taplin Biological Mass Spectrometry Facility (Boston, MA) as described previously (Yuan et al., 2005) .
Immunostaining, Immunoprecipitation, Western Blot, Peptide Slot Blot, ChIP, DNA Binding, and Luciferase Reporter Assays Cell (HeLa or 2fTGH) immunostaining was performed as described (Yuan et al., 2005) . CBP and DAPI probing was preceded by in situ cell fractionation. Confocal sections were obtained with a LeicaTCS SP2 AOBS confocal laser microscope by sequential scanning. For immunoprecipitation and western blot, cells were lysed in RIPA buffer. Approximately 4 mg of protein was incubated with 4 mg of monoclonal anti-IFNaR2, anti-Myc, anti-IRF9, or polyclonal anti-STAT2 for 6 hr or overnight at 4 C. Immunocomplexes were collected on protein G-agarose beads separated by 8%-10% SDS-PAGE and electroblotted to nitrocellulose membrane. Proteins were detected after incubation with specific antibodies described about or antiacetylated lysine and followed by Alex680-or IR700-conjugated secondary antibody for LICOR analysis. For peptide dot blot assay, three dilutions of the four peptides with the indicated modifications were spotted onto a nitrocellulose membrane. Such prepared membranes were incubated with whole cell extracts followed by three washes and anti-Myc immunoblotting analysis. The 4 peptides of 12 amino acid residues were synthesized as CERRKSPLQDPF, CERRaceKSPLQDPF, CERRKphoSPLQDPF, and CERRaceKphoSPLQDPF, purified with HPLC up to 98% purity. ChIP assay was carried out according to the manufacturer's protocol (Upstate). In brief, cells were left untreated or treated with IFNa (1000 U/ml) for 1 hr. Histone and DNA were crosslinked by adding 1% formaldehyde, and the cell lysates were made with SDS lysis buffer for sonication. Following immunoprecipitation of the diluted lysates with anti-ISGF3 (anti-IRF9/anti-STAT2), the eluates were reversed crosslinks and subjected to PCR (21 cycle) with the primers for 6À16 promoter (5 0 -GGTGAAAGGCCTGTGTGCC-3 0 and 5 0 -CAGC GAGTAAACGGTTCTCCG-3 0 ). For the electrophoretic mobility shift assay (EMSA), nuclear extracts were prepared from U2A or U5A transfectants and incubated for 20 min at room temperature with [a 32 P]dCTP-or biotin-labeled double-stranded oligonucleotide probe representing the ISRE site from the ISG15 gene 5 0 -GGGAAAGG GAAACCGAAACTGAA (À114/À92). Antibodies were incubated with nuclear extract 60 min prior to the addition of probe for supershift. For luciferase reporter assay, cells were transfected with ISG54-promoter luciferase reporter and cDNAs for test by the lipofectamine method in triplicates. Cellular extracts were collected 24 hr after transfection for luminescent luciferase analysis measured with commercial reagents (Promega, Madison, WI).
CBP siRNA Knockdown, RT-PCR, and Antiviral Activity Assays Cells (1 3 10 6 ) in 6-well dishes were transiently transfected with 15 nM 20-25 nt siRNA specific for CBP or control 20-25 nt siRNA (Santa Cruz Biotechnology, Santa Cruz, CA) by the lipofectamine method. Whole cell extracts were prepared 48 hr after transfection for immunoprecipitation and/or western blot analysis as described in the text. To analyze antiviral genes, 2fTGH, U2A, U5A, and U6A cells in 6-well dishes were treated with or without 1000 IU/ml of IFNa for 12 hr and total RNA was isolated using Trizol reagent (Invitrogen) according to the manufacturer's protocol. One microgram of total RNA was reversely transcribed into cDNA using the Clontech RT kit and random primer (Promega). RT-PCR primers for antiviral genes were described previously ( Figure S5B ). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) with forward 5 0 -TTCCTCTCCTCGCTCCAGTC -3 0 and reverse 5 0 -AGT GCGAGCCCTGACTTCCT -3 0 was used as a control. PCR was performed in a final volume of 25 ml containing 0.4 mM of each primer and 1 ml of template cDNA. IFNa antiviral responses were measured by vesicular stomatitis virus (VSV)-pseudotyped HIV-1 infection assay (Sancho et al., 2004) . In brief, pNL4-3.Luc.R-E-(pNL4-3 nef gene inserted with the firefly luciferase gene) and the pcDNA3-VSV plasmid encoding the vesicular stomatitis virus G protein were cotransfected in 293T cells using the lipofectamine 2000. The cell-free supernatants containing the virus stocks were collected 48 hr after transfection. U5A, U2A, or U6A transfectants in 12-well dishes were pretreated with or without IFNa for 12 hr followed by inoculating with the viruses stocks and 10 mg/ml polybrene for an additional 24 hr. The cells were washed with phosphate-buffered saline and lysed in 100 ml of passive lysis buffer for luciferase activity analysis by adding 100 ml substrates.
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